https://www.selleckchem.com/pr....oducts/pyrintegrin.h
Reduction of inflammation with colchicine has emerged as a therapeutic option for secondary prevention of cardiovascular disease (CVD) in patients with coronary artery disease (CAD). Our objective was to consolidate evidence from randomized controlled trials (RCTs) evaluating the efficacy and safety of low-dose colchicine for secondary prevention of CVD among patients with CAD on standard medical therapy. RCTs comparing the incidence of cardiovascular (CV) events between patients with clinically manifest CAD randomized to colchicine
Like
Comment
Share
